Cellectar Biosciences, Inc. (CLRB)

Oncology Corporate Profile

Stock Performance

1.7500
-0.1100

HQ Location

3301 Agriculture Drive
Madison, WI 53716

Company Description

Cellectar Biosciences is developing agents to detect, treat and monitor a broad spectrum of cancers. Utilizing a novel phospholipid ether (PLE) platform technology as a targeted delivery and retention vehicle, Cellectar_†_s compounds are designed to be selectively taken up and retained in both cancer cells and cancer stem cells. With the ability to attach both imaging and therapeutic agents to its proprietary delivery platform, Cellectar has developed a portfolio of product candidates engineered to capitalize on the unique characteristics of cancer cells to _†_find, treat and follow_†? malignancies in a highly selective way.

Website: http://www.cellectar.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
I-124-CLR1404positron emission tomography (PET)Glioblastoma Multiforme (GBM)II
I-131-CLR1404radiotherapeuticMultiple MyelomaI
I-124-CLR1404positron emission tomography (PET)Various cancer typesI
CLR-131cytotoxic radioisotopeMultiple Myeloma

View additional information on product candidates here »

Source


http://www.cellectar.com

Recent News Headlines

Cellectar Biosciences Further Deepens Intellectual Property Portfolio with Patent Grant for PET Imaging PDC

3/21/2017 12:03 pm

[GlobeNewswire] - MADISON, Wis., March 21, 2017-- Cellectar Biosciences, Inc., an oncology-focused, clinical stage biotechnology company, today announces the United States Patent and Trademark Office has granted a method ...

Cellectar Biosciences Reports 2016 Company Performance and Continued Progress in First Quarter 2017

3/15/2017 08:01 pm

[GlobeNewswire] - MADISON, Wis., March 15, 2017-- Cellectar Biosciences, Inc.,, an oncology-focused, clinical stage biotechnology company, today announces financial results for the year ending December 31, 2016. Management ...

Newly Issued Japanese Patent For PDC Optical Agents Further Strengthens Cellectar Biosciences’ Intellectual Property Portfolio

3/14/2017 12:03 pm

[GlobeNewswire] - MADISON, Wis., March 14, 2017-- Cellectar Biosciences, Inc., an oncology-focused, clinical stage biotechnology company, today announces the Japanese Patent Office has granted a composition of matter patent ...

Cellectar Biosciences to Host Conference Call on March 15 to Report Fourth Quarter and Year-End 2016 Financial Results and Corporate Performance

3/9/2017 01:03 pm

[GlobeNewswire] - MADISON, Wis., March 09, 2017-- Cellectar Biosciences, Inc.,, an oncology-focused, clinical stage biotechnology company, today announces that management will host a teleconference and live webcast to report ...

Expanding Its Strategic Relationship with Wisconsin Alumni Research Foundation (WARF), Cellectar Biosciences Executes New License Agreement

3/8/2017 01:00 pm

[GlobeNewswire] - MADISON, Wis., March 08, 2017-- Cellectar Biosciences, Inc., an oncology-focused, clinical stage biotechnology company, today announces it has entered into a licensing agreement with the Wisconsin Alumni ...

Cellectar Biosciences to Present at 29th Annual Roth Conference

3/6/2017 01:03 pm

[GlobeNewswire] - MADISON, Wis., March 06, 2017-- Cellectar Biosciences, Inc., an oncology-focused, clinical stage biotechnology company, announces today that its president and CEO, Jim Caruso, will present at the 29 th ...

Cellectar Biosciences Provides Phase I Trial Update of CLR 131 in Multiple Myeloma: Median Progression-Free Survival Extends to 133 Days, Median Overall Survival Reaches 17.7 Months

2/27/2017 01:00 pm

[GlobeNewswire] - MADISON, Wis., Feb. 27, 2017-- Cellectar Biosciences, Inc., an oncology-focused clinical stage biotechnology company, today provides an update of its Phase I clinical study of CLR 131 in patients with ...

Upon Successful Completion of Cohort 3, Cellectar Biosciences Initiates Fourth Cohort of Its Phase I Clinical Trial of CLR 131 in Multiple Myeloma

2/22/2017 01:03 pm

[GlobeNewswire] - MADISON, Wis., Feb. 22, 2017-- Cellectar Biosciences, Inc., an oncology-focused clinical stage biotechnology company, today announces the successful completion of Cohort 3 and initiation of Cohort 4 in ...

UPDATE -- Cellectar Biosciences to Present at 2017 BIO CEO & Investor Conference

2/13/2017 12:00 pm

[GlobeNewswire] - MADISON, Wis., Feb. 13, 2017-- Cellectar Biosciences, Inc., an oncology-focused, clinical stage biotechnology company, announced today that its president and CEO, Jim Caruso, will present at the 2017 BIO ...

Cellectar Biosciences to Present at the 2nd Annual Disruptive Growth & Healthcare Conference

2/9/2017 01:03 pm

[Accesswire] - NEW YORK, NY / ACCESSWIRE / February 9, 2017 / Cellectar Biosciences (NASDAQ: CLRB), an oncology-focused, clinical stage biotechnology company, announces today that it will be presenting at the 2nd Annual ...